“…The observed alfaxalone induction doses (1.75 mg/kg -3.00 mg/kg) are similar to those reported in earlier studies in other species such as: sheep Torres et al 2012); dogs (Maddern et al 2010;Suarez et al 2012); and ponies (Klöppel & Leece 2011;Leece et al 2009), but lower than doses reported in cats (Martinez Taboada & Murison 2010;Mathis et al 2012). The reason for the lack of agreement in alfaxalone dose could be the difference in the rate at which alfaxalone was administered.…”
Section: Discussionsupporting
confidence: 86%
“…In goats, induction of general anaesthesia can be achieved by administration of ketamine, propofol or thiopentone (Dzikiti 2013;Prassinos et al 2005). Recently, alfaxalone has been shown to be an alternative induction agent in: dogs (Ferré et al 2006;Muir et al 2008;Suarez et al 2012); cats ; sheep ); ponies (Klöppel & Leece 2011;Leece et al 2009); and horses (Goodwin et al 2011). However, its efficacy as an induction agent in goats has not yet been reported.…”
Section: Introductionmentioning
confidence: 96%
“…Its pharmacokinetic and pharmacodynamic profiles make it ideal for intravenous induction and maintenance of general anaesthesia in dogs (Ambrisko et al 2011;Ambros et al 2008;Ferré et al 2006;Jiménez et al 2012;Maddern et al 2010;Michou et al 2012;Muir et al 2008;Psatha et al 2011;Rodríguez et al 2012;Suarez et al 2012). Alfaxalone has been reported to be a suitable anaesthetic-induction agent at a dose of 2.00 mg/kg in unsedated sheep , Torres et al 2012, sedated dogs (Maddern et al 2009;Suarez et al 2012) and ponies (Klöppel & Leece 2011;Leece et al 2010 To the knowledge of the authors, there are currently no scientific reports on the effects of commonly used sedatives on the induction dose of alfaxalone in goats, as well as the impact of these agents on the quality of general anaesthesia arising from their use. The present study tested the null hypothesis that midazolam, alone or combined with butorphanol, does not affect the induction dose of alfaxalone versus the alternative hypothesis that midazolam and butorphanol affect the alfaxalone induction dose in goats.…”
Goats are rarely anaesthetised; consequently, scant information is available on the efficacy of anaesthetic drugs in this species. Alfaxalone is a relatively new anaesthetic agent, of which the efficacy in goats has not yet been studied. In this study, the sedative and alfaxalone sparing effects of midazolam and butorphanol, administered alone or concomitantly, in goats were assessed. Eight clinically healthy goats, four does and four wethers, were enlisted in a randomised crossover manner to receive intramuscular sedative treatments consisting of saline 0.05 mL/kg, or midazolam 0.30 mg/kg, or butorphanol 0.10 mg/kg, or a combination of midazolam 0.30 mg/kg with butorphanol 0.10 mg/kg before intravenous induction of general anaesthesia with alfaxalone. Following induction, the goats were immediately intubated and the quality of anaesthesia and basic physiological cardiorespiratory and blood-gas parameters were assessed until the goats had recovered from anaesthesia. The degree of sedation, quality of induction and recovery were scored. When compared with saline (3.00 mg/kg), midazolam,administered alone or with butorphanol, caused a statistically significant increased level of sedation and a reduction in the amount of alfaxalone required for induction (2.00 mg/kg and 1.70 mg/kg, respectively). Butorphanol alone (2.30 mg/kg) did not cause significant changes in level of sedation or alfaxalone-induction dose. During induction and recovery, the goats were calm following all treatments, including the control group. Cardiorespiratory and blood-gas parameters were maintained within clinically acceptable limits. The present study showed that midazolam, administered alone or combined with butorphanol, produces a degree of sedation that significantly reduces the dose of alfaxalone required for induction of general anaesthesia in goats, without causing any major adverse cardiorespiratory effects.
“…The observed alfaxalone induction doses (1.75 mg/kg -3.00 mg/kg) are similar to those reported in earlier studies in other species such as: sheep Torres et al 2012); dogs (Maddern et al 2010;Suarez et al 2012); and ponies (Klöppel & Leece 2011;Leece et al 2009), but lower than doses reported in cats (Martinez Taboada & Murison 2010;Mathis et al 2012). The reason for the lack of agreement in alfaxalone dose could be the difference in the rate at which alfaxalone was administered.…”
Section: Discussionsupporting
confidence: 86%
“…In goats, induction of general anaesthesia can be achieved by administration of ketamine, propofol or thiopentone (Dzikiti 2013;Prassinos et al 2005). Recently, alfaxalone has been shown to be an alternative induction agent in: dogs (Ferré et al 2006;Muir et al 2008;Suarez et al 2012); cats ; sheep ); ponies (Klöppel & Leece 2011;Leece et al 2009); and horses (Goodwin et al 2011). However, its efficacy as an induction agent in goats has not yet been reported.…”
Section: Introductionmentioning
confidence: 96%
“…Its pharmacokinetic and pharmacodynamic profiles make it ideal for intravenous induction and maintenance of general anaesthesia in dogs (Ambrisko et al 2011;Ambros et al 2008;Ferré et al 2006;Jiménez et al 2012;Maddern et al 2010;Michou et al 2012;Muir et al 2008;Psatha et al 2011;Rodríguez et al 2012;Suarez et al 2012). Alfaxalone has been reported to be a suitable anaesthetic-induction agent at a dose of 2.00 mg/kg in unsedated sheep , Torres et al 2012, sedated dogs (Maddern et al 2009;Suarez et al 2012) and ponies (Klöppel & Leece 2011;Leece et al 2010 To the knowledge of the authors, there are currently no scientific reports on the effects of commonly used sedatives on the induction dose of alfaxalone in goats, as well as the impact of these agents on the quality of general anaesthesia arising from their use. The present study tested the null hypothesis that midazolam, alone or combined with butorphanol, does not affect the induction dose of alfaxalone versus the alternative hypothesis that midazolam and butorphanol affect the alfaxalone induction dose in goats.…”
Goats are rarely anaesthetised; consequently, scant information is available on the efficacy of anaesthetic drugs in this species. Alfaxalone is a relatively new anaesthetic agent, of which the efficacy in goats has not yet been studied. In this study, the sedative and alfaxalone sparing effects of midazolam and butorphanol, administered alone or concomitantly, in goats were assessed. Eight clinically healthy goats, four does and four wethers, were enlisted in a randomised crossover manner to receive intramuscular sedative treatments consisting of saline 0.05 mL/kg, or midazolam 0.30 mg/kg, or butorphanol 0.10 mg/kg, or a combination of midazolam 0.30 mg/kg with butorphanol 0.10 mg/kg before intravenous induction of general anaesthesia with alfaxalone. Following induction, the goats were immediately intubated and the quality of anaesthesia and basic physiological cardiorespiratory and blood-gas parameters were assessed until the goats had recovered from anaesthesia. The degree of sedation, quality of induction and recovery were scored. When compared with saline (3.00 mg/kg), midazolam,administered alone or with butorphanol, caused a statistically significant increased level of sedation and a reduction in the amount of alfaxalone required for induction (2.00 mg/kg and 1.70 mg/kg, respectively). Butorphanol alone (2.30 mg/kg) did not cause significant changes in level of sedation or alfaxalone-induction dose. During induction and recovery, the goats were calm following all treatments, including the control group. Cardiorespiratory and blood-gas parameters were maintained within clinically acceptable limits. The present study showed that midazolam, administered alone or combined with butorphanol, produces a degree of sedation that significantly reduces the dose of alfaxalone required for induction of general anaesthesia in goats, without causing any major adverse cardiorespiratory effects.
“…However, each time rescue is required, surgery is interrupted until the effect of the rescue drug develops, and the apparently longer BUT surgery time may simply be further reflection of the better surgical conditions in the BUP group. A need for additional doses of anaesthetic agent has often been reported in studies of field castration in ponies, even when a higher dose of butorphanol (50 μg/kg) was given (Corletto and others 2005, Leece and others 2009, Sanz and others 2009, Kloppel and Leece 2011), and the current study is no exception. It is surprising, however, that Corletto and others (2005) reported poorer anaesthetic quality after morphine (100 μg/kg) than butorphanol, whereas in the present study more anaesthetic was required after butorphanol than after buprenorphine.…”
Section: Discussionmentioning
confidence: 58%
“…However, μ-opioid receptor agonists are considered the best analgesics, and butorphanol is usually regarded as less effective in treating moderate to severe pain (Muir 1981, Wagner 1999). Although butorphanol has been shown to be a suitable opioid for horses undergoing castration (Corletto and others 2005, Leece and others 2009, Sanz and others 2009, Kloppel and Leece 2011), a μ-opioid receptor agonist might be more appropriate as the opioid component of preanaesthetic medication before a surgical procedure. The quality of sedation and surgical conditions with morphine, the gold standard μ-opioid receptor agonist, was inferior, although acceptable, to butorphanol; unfortunately postoperative analgesia was not reported (Corletto and others 2005).…”
A prospective, randomised, blinded, clinical trial in 47 ponies compared butorphanol and buprenorphine administered intravenously with detomidine prior to castration under anaesthesia. Detomidine 12 μg/kg intravenously was followed by butorphanol 25 μg/kg (BUT) or buprenorphine 5 μg/kg (BUP) before induction of anaesthesia with intravenous ketamine and diazepam. Quality of sedation, induction and recovery from anaesthesia, response to tactile stimulation, and surgical conditions were scored. If anaesthesia was inadequate 'rescue' was given with intravenous ketamine (maximum three doses) followed by intravenous thiopental and detomidine. Time from induction to first rescue, total ketamine dose and number of rescues were recorded. Postoperative locomotor activity was scored and abnormal behaviour noted. Simple descriptive scales were used for all scoring. Data were analysed using two-way analysis of variance, t tests, Mann-Whitney or Fisher's exact tests as appropriate; P<0.05 was considered statistically significant. Cryptorchid animals did not undergo surgery, but castration was successfully completed in 18 BUT and 20 BUP. More incremental ketamine (P=0.0310) and more rescue drugs (P=0.0165) were required in BUT and more postoperative locomotor activity occurred in BUP (P=0.0001). There were no other differences between groups. Both opioids were suitable for premedication prior to castration but buprenorphine appeared to provide better intraoperative analgesia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.